Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33 rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.

Oppenheimer 33 rd Annual Healthcare Conference
Presentation Details:
Date: Monday, March 13, 2023
Time: 12:40 – 1:10 PM ET
Format : Fireside Chat - William G. Rice, PhD, Chairman, President and Chief Executive Officer, Aptose, with Matthew Biegler, Senior Analyst, Emerging Biotechnology, Oppenheimer
Webcast: LINK

The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com .

The Aptose management team will be hosting virtual one-on-one meetings during the conference. To schedule a one-on-one meeting, please contact your conference representative.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (formerly HM43239), an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com .

For further information, please contact:
Aptose Biosciences Inc. LifeSci Advisors, LLC
Susan Pietropaolo Dan Ferry, Managing Director
Investor Relations 617-535-7746
201-923-2049 Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

APS:CA,APTO
The Conversation (0)
Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Spoken Nutrition™ is a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification, making Spoken products eligible for use by athletes in several major-league and minor-league organizations, as well as the NCAA. With purchase orders secured from many professional sports teams, including multiple MLB teams for use during Spring Training leading into the 2025 regular baseball season, the launch of Spoken Nutrition™ cements Cizzle Brands Corporation as a global leader in sports nutrition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

Spoken Nutrition™ is a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification, making Spoken products eligible for use by athletes in several major-league and minor-league organizations, as well as the NCAA. With purchase orders secured from many professional sports teams, including multiple MLB teams for use during Spring Training leading into the 2025 regular baseball season, the launch of Spoken Nutrition™ cements Cizzle Brands Corporation as a global leader in sports nutrition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

With the debut of CWENCH Hydration™ in its first major Canadian grocer, Cizzle Brands anticipates that it will be able to further penetrate the mainstream consumer market alongside the specialty athletic and fitness-related markets. Starting this month, CWENCH Hydration™ mix packets will be offered in the pharmacy section of 47 Metro supermarkets across the province of Ontario.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

With the debut of CWENCH Hydration™ in its first major Canadian grocer, Cizzle Brands anticipates that it will be able to further penetrate the mainstream consumer market alongside the specialty athletic and fitness-related markets. Starting this month, CWENCH Hydration™ mix packets will be offered in the pharmacy section of 47 Metro supermarkets across the province of Ontario.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks (Updated January 2025)

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three-year highs in response to breakthrough innovations and increased deals for biotech stocks on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a high of 4,954.813 on September 19, 2024. While the NBI is trading down at 4,399.36 as of January 7, 2025, further growth could be in store in the future. However, the current economic environment means the biotech sector may have a complex road ahead.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion.

Keep reading...Show less

Latest Press Releases

Related News

×